Search
Ancrod
go.drugbank.com/drugs/DB05099ApprovedWithdrawnCurrently, Viprinex®/ancrod is not approved or marketed in any country, but is being investigated as a stroke treatment in worldwide clinical trials. In January 2005, the U.S. … FDA granted a 'fast-track status' for investigation of ancrod use in patients suffering from acute ischemic stroke, a life threatening condition caused by the blockage of blood vessels supplying blood
Meprobamate
go.drugbank.com/drugs/DB00371ApprovedIllicitMeprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). … It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines.
Technetium Tc-99m sulfur colloid
go.drugbank.com/drugs/DB09397Approved(intraperitoneal injection), is taken up by reticulocytes (intravenous injection), or enters the gastroesphageal tract (oral administration). … This is possible as Technetium-99m decays by isomeric transition to technetium-99 through the release of a gamma ray.
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242000, A242005] [Interferon alfa-2b] has been used for decades to treat PV but requires frequent dosing and is not tolerated by all patients. … [A242010, A242015] Ropeginterferon alfa-2b was approved by the FDA on November 12, 2021, and is currently marketed under the trademark BESREMi by PharmaEssentia Corporation.[L39170]
Proguanil
go.drugbank.com/drugs/DB01131ApprovedIt does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.
Olutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigationalOlutasidenib (FT-2102) is a selective and potent isocitrate dehydrogenase-1 (IDH1) inhibitor approved by the FDA in December 2022. … [L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test.
Azelaic acid
go.drugbank.com/drugs/DB00548ApprovedInvestigationalIt is also produced by _Malassezia furfur_, also known as _Pityrosporum ovale_, which is a species of fungus that is normally found on human skin. … It works in part by stopping the growth of skin bacteria that cause acne, and by keeping skin pores clear.
Synonyms: n-nonanedioic acidMycophenolate mofetil
go.drugbank.com/drugs/DB00688ApprovedInvestigational[A180799,A180805] Previously, mycophenolic acid (MPA) was administered to individuals with autoimmune diseases beginning in the 1970s, but was discontinued due to gastrointestinal effects and concerns … [L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995.
Products: Co MycophenolateBucetin
go.drugbank.com/drugs/DB13278ApprovedWithdrawnBucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.[A175636]
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … immune dysregulation by shifting the balance between Th17 cells and T-regulatory cells, thereby dampening the inflammatory cascade that can occasionally be fatal.